Effects of human immunodeficiency virus sera and macrophage supernatants on mesangial cell proliferation and matrix synthesis.
Patients with human immunodeficiency virus (HIV) infection are prone to the development of focal segmental glomerulosclerosis, a lesion in which increased mesangial cell proliferation and matrix synthesis may play a role. We undertook the present study to determine whether HIV sera may affect mesangial cell proliferation and matrix synthesis either directly or indirectly via effects on macrophage supernatants. Pooled HIV sera was found to significantly enhance (P < 0.01) mesangial cell proliferation in a concentration-related manner. Mesangial cell proliferation was significantly suppressed by two medications commonly utilized in HIV-infected patients, azidothymidine and trimethoprim/sulfamethoxazole, and was not significantly altered by lipopolysaccharide, suggesting that these medications as well as recurrent infection are unlikely to account for the proliferative effect of HIV sera. Supernatants from HIV sera-treated macrophages were found to significantly enhance (P < 0.01) mesangial cell incorporation of [3H]proline, a marker for synthesis of the matrix component collagen, compared to supernatants from control sera-treated macrophages. These results suggest that HIV sera may directly enhance mesangial cell proliferation and may indirectly increase mesangial cell matrix synthesis by altering macrophage secretory products. These effects may play a role in the development of glomerulosclerosis in patients with HIV infection.
Mattana
J
J
Department of Medicine, Long Island Jewish Medical Center, New Hyde Park, New York 11042.
Abramovici
M
M
Singhal
P C
PC
D002455:Cell Division / Q000502:physiology; D002478:Cells, Cultured; D016326:Extracellular Matrix Proteins / Q000096:biosynthesis*; D005920:Glomerular Mesangium / Q000187:drug effects / Q000378:metabolism* / Q000473:pathology*; D015658:HIV Infections / Q000097:blood*; D006801:Humans; D008070:Lipopolysaccharides / Q000494:pharmacology; D008264:Macrophages / Q000187:drug effects / Q000378:metabolism*; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000494:pharmacology; D015215:Zidovudine / Q000494:pharmacology
D016326:Extracellular Matrix Proteins; D008070:Lipopolysaccharides; D015215:Zidovudine; D015662:Trimethoprim, Sulfamethoxazole Drug Combination